We are also working on new formulations, including a fully liquid presentation of our tetravalent vaccine for MenACWY, Menveo, which is expected to enter phase II clinical trials in 2018. The results from our phase III study of our booster for Menveo are expected in 2018. We are also ...
The article reports that meningitis vaccine Menveo from Swiss drug maker Novartis AG has been shown to be effective in infants. According to data to be published in the January 2008 issue of the "Journal of the American Medical Association," the vaccine showed generated protective immune responses...
We are also working on new formulations, including a fully liquid presentation of our tetravalent vaccine for MenACWY, Menveo, which is expected to enter phase II clinical trials in 2018. The results from our phase III study of our booster for Menveo are expected in 2018. We are also ...
Opinion: Novartis: Menveo is ready to be submitted.The article reports on the proven efficacy of meningcoccal vaccine developed by Novartis AG called Menveo. The vaccine is effective in infants and older persons based on trials it had undergone wherein it has been shown to improve on the ...